Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE ... drugs Mounjaro and Zepbound. These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

Eli Lilly stock has been a big-time winner ... has been the blockbuster drugs Mounjaro and Zepbound. These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which compete directly with ...

Eli Lilly and Co. (LLY ... drug could disrupt the injectable market like Lilly’s Mounjaro and Novo’s Wegovy. However, with Pfizer out of the picture, Lilly now faces less competition in ...

Learn More » Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE ... These are Lilly's glucagon-like peptide-1 (GLP-1) medicines, which compete directly ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on Thursday that its experimental pill — called orforglipron — is showing ...

Eli Lilly will use BigHat’s AI-driven Milliner platform. Credit: Just_Super via Getty Images. Eli Lilly has signed a new research ... as high-profile results from Eli Lilly’s oral glucagon-like ...

Eli Lilly’s stock was up 13.8% at market open today following the news. Image credit: Shutterstock / Tada Images. Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE ... Phase 3 trial." As Lilly described in its press release, orforglipron is "the first oral small molecule glucagon-like peptide ...

Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made ...